Use of journal articles for off-label promotion hits snag

04/21/2008 | NYTimes.com

The FDA's proposal to allow drug firms to use medical journal articles to promote the off-label use of treatments has suffered another setback with a recent report that claims Merck & Co. hired ghostwriters to write journal articles to support the drug Vioxx. Health officials and medical specialists say the accusations raise questions about the transparency of peer reviews and the agency's dependence on published research to provide evidence on the safety of off-label drug use.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations